Big changes in biologics in this week's column, as we round up the pharma industry's new scientific hires.
Oxford BioTherapeutics, a company developing antibody-drug conjugates (ADCs) for cancer, has appointed Keith Wilson as Chief Scientific Officer (CSO). He joins the company from AbbVie, where he was Global Leader for Antibody Drug Conjugates.
Wilson has worked in life sciences R&D for more than 20 years, specialising in oncology and immunology. Before AbbVie, he worked as Senior Director of Research at Facet Biotech, and Director of Pipeline Strategy, Early Discovery and Computational Biology at PDL BioPharma.
Oxford BioTherapeutics’ proprietary ADC platform, named OGAP, uses the company’s proteomic databases, with data on over 5,000 cancer cell proteins, to identify ADV activity.
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions